Zota Health Care Limited
NSE: ZOTA · Pharmaceuticals
Snapshot
Unlock Zota Health Care Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Zota Health Care Limited is a pharmaceutical company engaged in the development, manufacturing, and marketing of generic, over-the-counter, ayurvedic, and nutraceutical products. The company also operates a significant retail pharmacy chain under the DAVAINDIA brand across India.
Business Model
The company generates revenue through the manufacturing and sale of pharmaceutical products and the operation of a retail pharmacy network. Its business model integrates product development with a direct-to-consumer retail strategy.
- Retail Stores:591
- States of Operation:24
Growth Outlook
Growth is driven by the expansion of the DAVAINDIA retail footprint and the continued development of medicines for chronic illnesses such as diabetes and heart disease. The company aims to leverage its diverse product portfolio to capture market share in the Indian pharmaceutical sector.
Key Risks
- Regulatory Compliance. The pharmaceutical industry is subject to stringent government regulations and quality standards that can impact manufacturing and distribution.
- Competitive Pressure. The company faces intense competition from both large established pharmaceutical firms and numerous unorganised retail pharmacy players.
- Supply Chain Disruptions. Dependence on raw material procurement and logistics for its retail network makes the company vulnerable to supply chain volatility.
- Pricing Controls. Government-mandated price caps on essential medicines can significantly compress profit margins for pharmaceutical manufacturers.
Price
Start your research today
Unlock AI insights, financials, peers and live data on Zota Health Care Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹539 Cr
TTM · consolidated
NET PROFIT
₹-74 Cr
TTM · consolidated
EPS
₹-23.75
TTM · consolidated
RETURN ON EQUITY
-21.7%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
8.7%
TTM · standalone
P/E
-57.7x
Q4 FY26 · consolidated
EV/EBITDA
160.7x
Q4 FY26 · consolidated
EBITDA MARGIN
4.8%
TTM · consolidated
NET PROFIT MARGIN
-8.9%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.0x
Q4 FY26 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap (Cr) | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Zota Health Care LimitedZOTA | 3,596 | -57.68 | 160.70 | 83.9% | 4.8% | -21.7% | 8.7% | +16.9% |
Innova Captab LimitedINNOVACAP | 3,954 | 41.08 | 24.48 | 31.1% | 15.4% | 14.2% | 16.3% | +11.7% |
SMS Pharmaceuticals LimitedSMSPHARMA | 3,722 | 34.20 | 21.96 | 13.3% | 20.3% | 15.1% | 16.0% | +57.8% |
Sun Pharma Advanced Research Company LimitedSPARC | 3,663 | 5.23 | 5.39 | 2518.3% | 85.7% | 903.1% | 488.1% | +53.6% |
Senores Pharmaceuticals Ltd.SENORES | 3,407 | 55.05 | 32.37 | — | 33.2% | 14.8% | 17.8% | +135.5% |
Aarti Drugs LimitedAARTIDRUGS | 3,074 | 22.64 | 16.14 | 4.0% | 11.6% | 13.1% | 13.0% | -19.3% |
As of Q4 FY26
Financials
Zota Health Care Limited
NSE: ZOTA · Pharmaceuticals
Snapshot
Unlock Zota Health Care Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Zota Health Care Limited is a pharmaceutical company engaged in the development, manufacturing, and marketing of generic, over-the-counter, ayurvedic, and nutraceutical products. The company also operates a significant retail pharmacy chain under the DAVAINDIA brand across India.
Business Model
The company generates revenue through the manufacturing and sale of pharmaceutical products and the operation of a retail pharmacy network. Its business model integrates product development with a direct-to-consumer retail strategy.
- Retail Stores:591
- States of Operation:24
Growth Outlook
Growth is driven by the expansion of the DAVAINDIA retail footprint and the continued development of medicines for chronic illnesses such as diabetes and heart disease. The company aims to leverage its diverse product portfolio to capture market share in the Indian pharmaceutical sector.
Key Risks
- Regulatory Compliance. The pharmaceutical industry is subject to stringent government regulations and quality standards that can impact manufacturing and distribution.
- Competitive Pressure. The company faces intense competition from both large established pharmaceutical firms and numerous unorganised retail pharmacy players.
- Supply Chain Disruptions. Dependence on raw material procurement and logistics for its retail network makes the company vulnerable to supply chain volatility.
- Pricing Controls. Government-mandated price caps on essential medicines can significantly compress profit margins for pharmaceutical manufacturers.
Price
Loading…
Start your research today
Unlock AI insights, financials, peers and live data on Zota Health Care Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹539 Cr
TTM · consolidated
NET PROFIT
₹-74 Cr
TTM · consolidated
EPS
₹-23.75
TTM · consolidated
RETURN ON EQUITY
-21.7%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
8.7%
TTM · standalone
P/E
-57.7x
Q4 FY26 · consolidated
EV/EBITDA
160.7x
Q4 FY26 · consolidated
EBITDA MARGIN
4.8%
TTM · consolidated
NET PROFIT MARGIN
-8.9%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.0x
Q4 FY26 · consolidated
Peers · Pharmaceuticals
As of Q4 FY26